Experience with the histrelin implant in pediatric patients

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The histrelin implant has emerged as a therapeutic option for the treatment of central precocious puberty that has been favorably received by patients and providers. Inserted subcutaneously, the 50-mg implant provides continuous release of the potent gonadotropin-releasing hormone analog (GnRHa) histrelin. Profound suppression of the hypothalamic-pituitary-gonadal (HPG) axis occurs within 1 month of its placement resulting in pubertal arrest, attenuation of skeletal advancement and a progressive increase in predicted adult height. Although marketed for annual use, suppression lasting 2 years from a single implant has been demonstrated. Placing and removing the device is a minor outpatient procedure easily accomplished by a pediatric surgeon using local anesthesia. The major downside to the implant is a ∼25% rate of breakage upon removal. Information about the recovery of the HPG axis following histrelin explantation is limited but suggests an average time to menarche comparable with depot GnRHa formulations albeit with wide individual variation.

Original languageEnglish (US)
Pages (from-to)54-59
Number of pages6
JournalEndocrine Development
Volume30
DOIs
StatePublished - 2016

Fingerprint

Pediatrics
Gonadotropin-Releasing Hormone
Menarche
Local Anesthesia
Outpatients
Equipment and Supplies
Therapeutics
histrelin
Central Precocious Puberty
Surgeons

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health
  • Endocrinology
  • Endocrine and Autonomic Systems

Cite this

Experience with the histrelin implant in pediatric patients. / Eugster, Erica.

In: Endocrine Development, Vol. 30, 2016, p. 54-59.

Research output: Contribution to journalArticle

@article{5a64dabd9d5f45d5a2e3fa5f5fec9276,
title = "Experience with the histrelin implant in pediatric patients",
abstract = "The histrelin implant has emerged as a therapeutic option for the treatment of central precocious puberty that has been favorably received by patients and providers. Inserted subcutaneously, the 50-mg implant provides continuous release of the potent gonadotropin-releasing hormone analog (GnRHa) histrelin. Profound suppression of the hypothalamic-pituitary-gonadal (HPG) axis occurs within 1 month of its placement resulting in pubertal arrest, attenuation of skeletal advancement and a progressive increase in predicted adult height. Although marketed for annual use, suppression lasting 2 years from a single implant has been demonstrated. Placing and removing the device is a minor outpatient procedure easily accomplished by a pediatric surgeon using local anesthesia. The major downside to the implant is a ∼25{\%} rate of breakage upon removal. Information about the recovery of the HPG axis following histrelin explantation is limited but suggests an average time to menarche comparable with depot GnRHa formulations albeit with wide individual variation.",
author = "Erica Eugster",
year = "2016",
doi = "10.1159/000439330",
language = "English (US)",
volume = "30",
pages = "54--59",
journal = "Endocrine Development",
issn = "1421-7082",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Experience with the histrelin implant in pediatric patients

AU - Eugster, Erica

PY - 2016

Y1 - 2016

N2 - The histrelin implant has emerged as a therapeutic option for the treatment of central precocious puberty that has been favorably received by patients and providers. Inserted subcutaneously, the 50-mg implant provides continuous release of the potent gonadotropin-releasing hormone analog (GnRHa) histrelin. Profound suppression of the hypothalamic-pituitary-gonadal (HPG) axis occurs within 1 month of its placement resulting in pubertal arrest, attenuation of skeletal advancement and a progressive increase in predicted adult height. Although marketed for annual use, suppression lasting 2 years from a single implant has been demonstrated. Placing and removing the device is a minor outpatient procedure easily accomplished by a pediatric surgeon using local anesthesia. The major downside to the implant is a ∼25% rate of breakage upon removal. Information about the recovery of the HPG axis following histrelin explantation is limited but suggests an average time to menarche comparable with depot GnRHa formulations albeit with wide individual variation.

AB - The histrelin implant has emerged as a therapeutic option for the treatment of central precocious puberty that has been favorably received by patients and providers. Inserted subcutaneously, the 50-mg implant provides continuous release of the potent gonadotropin-releasing hormone analog (GnRHa) histrelin. Profound suppression of the hypothalamic-pituitary-gonadal (HPG) axis occurs within 1 month of its placement resulting in pubertal arrest, attenuation of skeletal advancement and a progressive increase in predicted adult height. Although marketed for annual use, suppression lasting 2 years from a single implant has been demonstrated. Placing and removing the device is a minor outpatient procedure easily accomplished by a pediatric surgeon using local anesthesia. The major downside to the implant is a ∼25% rate of breakage upon removal. Information about the recovery of the HPG axis following histrelin explantation is limited but suggests an average time to menarche comparable with depot GnRHa formulations albeit with wide individual variation.

UR - http://www.scopus.com/inward/record.url?scp=84951196283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951196283&partnerID=8YFLogxK

U2 - 10.1159/000439330

DO - 10.1159/000439330

M3 - Article

C2 - 26683629

AN - SCOPUS:84951196283

VL - 30

SP - 54

EP - 59

JO - Endocrine Development

JF - Endocrine Development

SN - 1421-7082

ER -